TW200507874A - Immunostimulatory nucleic acid oil-in-water formulations and related methods of use - Google Patents

Immunostimulatory nucleic acid oil-in-water formulations and related methods of use

Info

Publication number
TW200507874A
TW200507874A TW093109204A TW93109204A TW200507874A TW 200507874 A TW200507874 A TW 200507874A TW 093109204 A TW093109204 A TW 093109204A TW 93109204 A TW93109204 A TW 93109204A TW 200507874 A TW200507874 A TW 200507874A
Authority
TW
Taiwan
Prior art keywords
nucleic acid
immunostimulatory nucleic
related methods
acid oil
water formulations
Prior art date
Application number
TW093109204A
Other languages
English (en)
Inventor
Heather L Davis
Michael J Mccluskie
Original Assignee
Coley Pharmaceutical Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharmaceutical Group Ltd filed Critical Coley Pharmaceutical Group Ltd
Publication of TW200507874A publication Critical patent/TW200507874A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW093109204A 2003-04-02 2004-04-02 Immunostimulatory nucleic acid oil-in-water formulations and related methods of use TW200507874A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45992003P 2003-04-02 2003-04-02
US46190303P 2003-04-10 2003-04-10

Publications (1)

Publication Number Publication Date
TW200507874A true TW200507874A (en) 2005-03-01

Family

ID=33135139

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093109204A TW200507874A (en) 2003-04-02 2004-04-02 Immunostimulatory nucleic acid oil-in-water formulations and related methods of use

Country Status (6)

Country Link
US (2) US20040235770A1 (zh)
EP (1) EP1608403A2 (zh)
AU (1) AU2004226605A1 (zh)
CA (1) CA2521050A1 (zh)
TW (1) TW200507874A (zh)
WO (1) WO2004087203A2 (zh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
NZ508927A (en) 1998-05-22 2003-12-19 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
JP5084984B2 (ja) 1999-02-17 2012-11-28 シーエスエル、リミテッド 免疫原複合体およびそれに関する方法
RU2245149C2 (ru) * 1999-09-25 2005-01-27 Юниверсити Оф Айова Рисерч Фаундейшн Иммуностимулирующие нуклеиновые кислоты
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
JP2003535907A (ja) 2000-06-22 2003-12-02 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 抗体誘導性細胞溶解を促進し、そして癌を処置するための方法
CA2419894A1 (en) 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh Process for high throughput screening of cpg-based immuno-agonist/antagonist
IL160157A0 (en) 2001-08-17 2004-07-25 Coley Pharm Group Inc Combination motif immune stimulation oligonucleotides with improved activity
NZ573064A (en) 2002-04-04 2011-02-25 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CA2494508A1 (en) * 2002-07-03 2004-01-15 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
BR0315810A (pt) 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-CPG NUCLEIC ACIDS AND USE METHOD
EA200600069A1 (ru) * 2003-06-20 2006-08-25 Коли Фармасьютикал Гмбх Низкомолекулярные антагонисты toll-подобных рецепторов (tlr)
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
SG123799A1 (en) * 2003-10-30 2006-07-26 Coley Pharm Gmbh C-class oligonucleotide analogs with enchanced immunostimulatory potency
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
PL2269622T3 (pl) 2005-07-01 2014-05-30 Index Pharmaceuticals Ab Sposób do modulowania wrażliwości na steroidy
DK2179737T3 (da) 2005-07-01 2013-11-11 Index Pharmaceuticals Ab Modulering af respons på steroider
EA013468B1 (ru) * 2005-09-16 2010-04-30 Коли Фармасьютикал Гмбх Иммуностимулирующая одноцепочечная рибонуклеиновая кислота с фосфодиэфирным остовом
WO2007031877A2 (en) * 2005-09-16 2007-03-22 Coley Pharmaceutical Gmbh Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
US8895522B2 (en) 2005-10-28 2014-11-25 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
CA2630738C (en) 2005-11-25 2013-09-03 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
US20080112974A1 (en) * 2006-09-08 2008-05-15 Duotol Ab Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
EP2494958A1 (en) 2006-12-01 2012-09-05 Anterios, Inc. Amphiphilic Entity Nanoparticles
US8119600B2 (en) * 2007-04-10 2012-02-21 Stefano Ferrari Compositions containing lysozyme and C-1/C-4 polysaccharides and use thereof in oral care, cosmetology and dermatology, contraception, urology and gynecology
ES2660906T3 (es) * 2007-05-31 2018-03-26 Anterios, Inc. Nanopartículas de ácido nucleico y usos de las mismas
CA2696460A1 (en) 2007-08-13 2009-02-19 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity
SI2200642T1 (sl) * 2007-10-19 2012-06-29 Novartis Ag Formulacije meningokoknega cepiva
RU2367458C1 (ru) * 2007-12-26 2009-09-20 Вагиф Султанович Султанов Лекарственное средство, фармацевтическая композиция, ингибитор роста helicobacter pylori и способ проведения антихеликобактерной терапии
RU2366442C1 (ru) * 2008-05-14 2009-09-10 Виктор Иванович Рощин Лекарственное средство, обладающее противопротозойной активностью в отношении trichomonas vaginalis в модельной системе in vitro
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
US20110236489A1 (en) * 2008-09-18 2011-09-29 Novartis Ag Vaccine adjuvant combinations
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
WO2010067262A1 (en) 2008-12-09 2010-06-17 Pfizer Inc. Immunostimulatory oligonucleotides
JP5759445B2 (ja) 2009-03-25 2015-08-05 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 病原体に対する哺乳類先天性免疫抵抗性の刺激のための組成物
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
KR102487144B1 (ko) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
US11723892B2 (en) * 2019-04-08 2023-08-15 Medpharm Holdings, Llc Brain health formulation
US20210393578A1 (en) * 2019-04-08 2021-12-23 Medpharm Holdings, Llc Brain health formulation
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9774A (en) * 1853-06-07 Machine for boring rock
US91097A (en) * 1869-06-08 Improvement in combined saw-set, gtjmmer, punch
US199466A (en) * 1878-01-22 Improvement in photographic vignetting devices
US176373A (en) * 1876-04-18 Improvement in tools for embossing eyelets
US191079A (en) * 1877-05-22 Improvement in nut-locks
US87534A (en) * 1869-03-09 Improvement in feather-renovators
US55477A (en) * 1866-06-12 Portable door-fastening
US125284A (en) * 1872-04-02 Improvement in concrete pavements
US162258A (en) * 1875-04-20 Improvement in toy pistols
US78223A (en) * 1868-05-26 Stephen b
US86839A (en) * 1869-02-09 Improvement in plows
US152656A (en) * 1874-06-30 Improvement in window-screens
US147468A (en) * 1874-02-17 Improvement in dumping-wagons
US87848A (en) * 1869-03-16 Improvement in harness-connection for looms
US152649A (en) * 1874-06-30 Improvement in preparing tobacco
US186921A (en) * 1877-02-06 Improvement in fruit-pickers
US28784A (en) * 1860-06-19 Cobosr-shellek
US152657A (en) * 1874-06-30 Improvement in bilge-water gages
US164341A (en) * 1875-06-08 Improvement in portable stoves
US224010A (en) * 1880-02-03 gilso n
US87538A (en) * 1869-03-09 Improvement in steam-engine rotary valves
US115219A (en) * 1871-05-23 Improvement in machines for trimming boot and shoe heels and sole-edges
US102255A (en) * 1870-04-26 Improved washing-machine
US139364A (en) * 1873-05-27 Improvement in carriage-protectors
US191833A (en) * 1877-06-12 Improvement in fruit-gatherers
US6034A (en) * 1849-01-16 Improvement in harvesting-machines
US64515A (en) * 1867-05-07 Impeovemeit
US212028A (en) * 1879-02-04 Improvement in seeding-machines
US216340A (en) * 1879-06-10 Improvement in holders for type for hand-stamps
US53880A (en) * 1866-04-10 Fire-place
US175731A (en) * 1876-04-04 Improvement in flying tops
US34330A (en) * 1862-02-04 Improvement in sewing-machines
US100527A (en) * 1870-03-08 James w
US125292A (en) * 1872-04-02 Improvement in brick-kilns
US41681A (en) * 1864-02-23 Improvement in sugar-cane mills
US139413A (en) * 1873-05-27 Improvement in dies for swaging carriage-clips
US162262A (en) * 1875-04-20 Improvement in hydraulic elevators
US104044A (en) * 1870-06-07 Improved adjustable hanger for shafting
US125279A (en) * 1872-04-02 Improvement in handles for brushes
US4062A (en) * 1845-05-29 Walter hunt
US4061A (en) * 1845-05-24 Spring-saddle
US148316A (en) * 1874-03-10 Improvement in try-squares and bevels
US104523A (en) * 1870-06-21 Improvement in refrigerating-attachment for wells
US64064A (en) * 1867-04-23 photo-utho
US212026A (en) * 1879-02-04 Improvement in processes of lining tubular fabrics with rubber
US46967A (en) * 1865-03-21 Assigrnob to benedict
US26782A (en) * 1860-01-10 Washbuen race
US26801A (en) * 1860-01-10 peters
US148976A (en) * 1874-03-24 Improvement in apparatus for capsuling bottles
US6032A (en) * 1849-01-16 Stop-cock wots
US22852A (en) * 1859-02-08 Improvement in photography on wood
US147870A (en) * 1874-02-24 Improvement in supplying air to air-chambers
US55014A (en) * 1866-05-22 Improved furnace for annealing sheet-iron
US91599A (en) * 1869-06-22 Improvement in low-water indicators
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5093318A (en) * 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US5308626A (en) * 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
ES2007350A6 (es) * 1987-05-29 1989-06-16 Ganadera Union Ind Agro Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion.
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5112605A (en) * 1989-03-17 1992-05-12 Genentech, Inc. Temporal gamma-interferon administration for allergies
US5178860A (en) * 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US5514577A (en) * 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US6042838A (en) * 1991-02-15 2000-03-28 Uab Research Foundation immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA)
US6030954A (en) * 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
SG54115A1 (en) * 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
FR2711670B1 (fr) * 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ES2267100T5 (es) * 1994-07-15 2011-04-08 The University Of Iowa Research Foundation Oligonucleótidos inmunomoduladores.
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US6027726A (en) * 1994-09-30 2000-02-22 Inex Phamaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US5753613A (en) * 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
US5858987A (en) * 1995-05-05 1999-01-12 Mitotix, Inc. E6AP antisense constructs and methods of use
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US6248720B1 (en) * 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US20030078223A1 (en) * 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
SE9600648D0 (sv) * 1996-02-21 1996-02-21 Bror Morein Receptorbimdande enhet
US6030955A (en) * 1996-03-21 2000-02-29 The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
JP4111403B2 (ja) * 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
CA2281838A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20030104044A1 (en) * 1997-05-14 2003-06-05 Semple Sean C. Compositions for stimulating cytokine secretion and inducing an immune response
US6339068B1 (en) * 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP1872786A1 (en) * 1997-09-05 2008-01-02 The Regents of the University of California Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
CA2323929C (en) * 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
NZ508927A (en) * 1998-05-22 2003-12-19 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ES2257068T3 (es) * 1998-08-10 2006-07-16 Antigenics Inc. Mezclas de adyuvantes de cpg y saponinas y metodos de empleo de las mismas.
US6210663B1 (en) * 1998-08-20 2001-04-03 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
US20020065236A1 (en) * 1998-09-09 2002-05-30 Yew Nelson S. CpG reduced plasmids and viral vectors
DE69915868T2 (de) * 1998-12-01 2005-03-17 Atropos Ltd., Bray Laparoskopische abgedichtete zugangsvorrichtung
KR100922031B1 (ko) * 1999-04-19 2009-10-19 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
US6737066B1 (en) * 1999-05-06 2004-05-18 The Immune Response Corporation HIV immunogenic compositions and methods
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
RU2245149C2 (ru) * 1999-09-25 2005-01-27 Юниверсити Оф Айова Рисерч Фаундейшн Иммуностимулирующие нуклеиновые кислоты
MXPA02005842A (es) * 1999-12-13 2003-10-14 Bioniche Life Sciences Inc Oligonucleotidos sinteticos terapeuticamente utiles.
US6852705B2 (en) * 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
EP1253947A4 (en) * 2000-01-31 2005-01-05 Univ California IMMUNOMODULATED POLYNUCLEOTIDES FOR THE TREATMENT OF INFECTIONS BY INTRA-CELLULAR DISEASES
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
WO2001072123A1 (en) * 2000-03-28 2001-10-04 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
DE60112073T2 (de) * 2000-05-12 2006-04-20 Pharmacia & Upjohn Co. Llc, Kalamazoo Impfstoffzusammensetzung und verfahren zur herstellung derselben sowie verfahren zur impfung von wirbeltieren
JP2003535907A (ja) * 2000-06-22 2003-12-02 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 抗体誘導性細胞溶解を促進し、そして癌を処置するための方法
WO2002018631A2 (de) * 2000-09-01 2002-03-07 Epigenomics Ag Diagnose von bestehenden erkrankungen oder der prädisposition für bestimmte erkrankungen
CA2419894A1 (en) * 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh Process for high throughput screening of cpg-based immuno-agonist/antagonist
DE60118228T2 (de) * 2000-09-28 2006-12-14 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Mikropartikel zur verabreichung von heterologen nukleinsäure
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
DK1889630T3 (da) * 2000-10-18 2012-03-05 Glaxosmithkline Biolog Sa Vacciner omfattende MAGE-antigen koblet til protein D-fragment
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
AU2002347062B2 (en) * 2001-10-06 2008-06-26 Merial Ltd CpG formulations and related methods
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
CA2388049A1 (en) * 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
CA2531280A1 (en) * 2002-07-03 2004-01-15 Cambridge Scientific, Inc. Vaccines to induce mucosal immunity
AU2003248921A1 (en) * 2002-07-09 2004-01-23 Point Therapeutics, Inc. Boroproline compound combination therapy
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
ES2547002T3 (es) * 2002-09-13 2015-09-30 Novartis Ag Beta-L-2' desoxinucleósidos para el tratamiento de cepas de VHB resistentes
US6988995B2 (en) * 2002-09-30 2006-01-24 Carl Zeiss Meditec, Inc. Method and system for detecting the effects of Alzheimer's disease in the human retina
BR0315810A (pt) * 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c
ES2351489T3 (es) * 2003-03-24 2011-02-07 Intercell Ag Vacunas mejoradas.
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
ATE476196T1 (de) * 2003-06-17 2010-08-15 Mannkind Corp Zusammensetzung zur auslösung, verbesserung und erhaltung von immunantworten gegen mhc-klasse-i- beschränkte epitope, für prophylaktische oder therapeutische zwecke
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
WO2005115449A1 (en) * 2004-05-28 2005-12-08 Alk-Abelló A/S Method of treating allergy and infection by eliciting an iga antibody response
US20070129320A9 (en) * 2004-07-18 2007-06-07 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US7601355B2 (en) * 2005-06-01 2009-10-13 Northwestern University Compositions and methods for altering immune function
EP1904530A2 (en) * 2005-07-07 2008-04-02 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
EP2360175B1 (en) * 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)

Also Published As

Publication number Publication date
US20040235770A1 (en) 2004-11-25
WO2004087203A3 (en) 2004-12-23
WO2004087203A2 (en) 2004-10-14
AU2004226605A1 (en) 2004-10-14
EP1608403A2 (en) 2005-12-28
US20090155307A1 (en) 2009-06-18
CA2521050A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
WO2003030934A3 (en) Cpg formulations and related methods
WO2018033254A3 (en) Rna for cancer therapy
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
TNSN07150A1 (en) Semi-soft c-class immunostimulatory oligonucleotides
EP1676512A3 (en) Skin treatment articles and methods
SG163583A1 (en) Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
MY165643A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
IN2005DE03350A (zh)
TW200510416A (en) P38 inhibitors and methods of use thereof
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
WO2007054283A3 (en) Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
WO2005123116A3 (en) Compositions and methods for treating or preventing oxalate-related disease
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
GB0109297D0 (en) Vaccine
SG167667A1 (en) Nucleic acid compositions for stimulating immune responses
ATE546153T1 (de) Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
WO2004067564A3 (en) Compositions against cancer antigen liv-1 and uses thereof
BR0111785A (pt) Composições e métodos para tratamento de candidìase
TW200504051A (en) Novel acridine derivatives and their use as medicaments